64cu-fapi-xt117
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 7, 2022 (NCT05814835)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05930457 | Phase 1 | Jul 26, 2023 | Guangzhou Medical University, Sinotau Pharmaceutical Group |
| NCT05814835 | Phase 1 | Dec 7, 2022 | People's Liberation Army of China, Sinotau Pharmaceutical Group |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sinotau Pharmaceutical Group | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1